KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $251.1 million.

  • Alnylam Pharmaceuticals' Income from Continuing Operations rose 32504.62% to $251.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 11311.16%. This contributed to the annual value of -$278.2 million for FY2024, which is 3681.73% up from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $251.1 million for Q3 2025, which was up 32504.62% from -$66.3 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Income from Continuing Operations' 5-year high stood at $251.1 million during Q3 2025, with a 5-year trough of -$405.9 million in Q3 2022.
  • For the 5-year period, Alnylam Pharmaceuticals' Income from Continuing Operations averaged around -$135.5 million, with its median value being -$174.1 million (2023).
  • Within the past 5 years, the most significant YoY rise in Alnylam Pharmaceuticals' Income from Continuing Operations was 32504.62% (2025), while the steepest drop was 29242.7% (2025).
  • Over the past 5 years, Alnylam Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$258.5 million in 2021, then rose by 19.72% to -$207.5 million in 2022, then skyrocketed by 33.55% to -$137.9 million in 2023, then skyrocketed by 39.24% to -$83.8 million in 2024, then skyrocketed by 399.76% to $251.1 million in 2025.
  • Its last three reported values are $251.1 million in Q3 2025, -$66.3 million for Q2 2025, and -$57.5 million during Q1 2025.